<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gadopiclenol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gadopiclenol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Gadopiclenol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="139754" href="/d/html/139754.html" rel="external">see "Gadopiclenol: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="139910" href="/d/html/139910.html" rel="external">see "Gadopiclenol: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F57242040"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Nephrogenic systemic fibrosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of gadolinium-based contrast agents in these patients unless the diagnostic information is essential and not available with noncontrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs.</p>
<p style="text-indent:-2em;margin-left:2em;">The risk for NSF appears highest among patients with chronic, severe kidney disease (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>) or acute kidney injury.</p>
<p style="text-indent:-2em;margin-left:2em;">Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (eg, &gt;60 years of age, hypertension, diabetes), estimate the GFR through laboratory testing.</p>
<p style="text-indent:-2em;margin-left:2em;">For patients at highest risk for NSF, do not exceed the recommended gadopiclenol dose and allow a sufficient period of time for elimination of the drug from the body prior to any readministration.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57397571"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Elucirem;</li>
<li>Vueway</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F57246865"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Diagnostic Agent;</li>
<li>
                        Gadolinium-Containing Contrast Agent;</li>
<li>
                        Macrocyclic Gadolinium-Based Contrast Agent;</li>
<li>
                        Radiological/Contrast Media (Nonionic, High Osmolality);</li>
<li>
                        Radiological/Contrast Media, Paramagnetic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F57284504"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a7a5a74a-f1f2-4c09-9d9a-4fcdcb5a0ed6">Body and CNS imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Body and CNS imaging: IV:</b> 0.05 mmol/kg (0.1 mL/kg) based on actual body weight as a single dose.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F57284506"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary, although there is increased exposure in patients with renal impairment (use is generally not recommended). In patients receiving hemodialysis, consider initiation of dialysis immediately following administration to enhance gadopiclenol elimination.</p></div>
<div class="block doha drugH1Div" id="F57284507"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F57284505"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F57298812"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="139910" href="/d/html/139910.html" rel="external">see "Gadopiclenol: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="72838891-aa81-4a68-b8e3-25dbf6c9059f">MRI, CNS and body imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>MRI, CNS and body imaging:</b> Dose based on actual body weight.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: IV: 0.05 mmol/kg (0.1 mL/kg); may begin imaging immediately after administration.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F57298813"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years and Adolescents: <b>Note:</b> Risk of nephrogenic systemic fibrosis (NSF) increases as renal function decreases. Consider risks versus benefits of diagnostic information prior to use.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to severe impairment: No dose adjustment recommended; avoid use when diagnostic information is not essential.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Dialyzable; in patients receiving hemodialysis, consider initiation of dialysis immediately following administration to enhance gadopiclenol elimination. Hemodialysis removes gadopiclenol from plasma at rates of 95% to 98% and 100% after the first and third hemodialysis sessions, respectively.</p></div>
<div class="block dohp drugH1Div" id="F57298814"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F57258235"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic dermatitis, erythema of skin, maculopapular rash, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, dysgeusia, nausea, oral paresthesia, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including injection-site coldness, injection-site paresthesia, pain at injection site, swelling at injection site, warm sensation at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, feeling hot, headache</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal function test abnormality (including increased Cystatin C and increased serum creatinine), renal insufficiency (worsening of)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Renal: Nephrogenic systemic fibrosis</p></div>
<div class="block coi drugH1Div" id="F57242044"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to gadopiclenol or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F57284492"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gadolinium retention: Gadolinium is retained for months or years in the brain, bone, skin, and other organs (kidney, liver, spleen); the highest concentration and longest duration have been found in the bone. Linear gadolinium-based contrast agents (GBCAs) (gadodiamide, gadoxetate disodium, gadobenate dimeglumine) result in more retention than macrocyclic GBCAs (gadoterate meglumine, gadobutrol, gadopiclenol, gadoteridol); among the linear agents, gadolinium retention varies, with gadodiamide causing greater retention than other linear agents. Pathologic and clinical consequences of gadolinium retention in skin and other organs have been established in patients with impaired kidney function; there also have been rare reports of pathologic skin changes in patients with normal kidney function. Consequences of gadolinium retention in the brain or in patients with normal kidney function have not been established. Patients with normal kidney function that may be at higher risk for gadolinium retention include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions; take GBCA retention characteristics into consideration for these patients. Minimize repetitive GBCA imaging studies.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity, including serious reactions, may occur; most reactions occurred within minutes of administration and resolved with emergency treatment. Appropriate equipment (eg, ventilator) and emergency medications (eg, epinephrine) should be available during use. Patients with a history of allergic reactions and/or bronchial asthma may be at an increased risk for developing hypersensitivity reactions; use caution in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrogenic systemic fibrosis: <b>[US Boxed Warning]: Risk of gadolinium-based contrast agent associated nephrogenic systemic fibrosis (NSF) is highest in patients with chronic, severe kidney dysfunction (GFR &lt;30 mL/minute/1.73m<sup>2</sup>) and acute kidney injury.</b> Avoid use unless diagnostic information cannot be obtained without use of a contrast MRI. Risk appears lower in patients with moderate, chronic kidney disease (GFR 30 to 59 mL/minute/1.73 m<sup>2</sup>) and little, if any, in patients with mild, chronic kidney disease (GFR 60 to 89 mL/minute/1.73 m<sup>2</sup>). NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs. Screen all patients for kidney dysfunction prior to administration; estimate GFR in patients at risk for chronic kidney disease (diabetes, chronic hypertension, age &gt;60 years). In patients at risk of NSF, do not exceed the recommended dosage and allow sufficient time (ie, several half-lives) for elimination prior to readministration (avoidance of readministration is preferred). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration to enhance contrast elimination.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with kidney impairment. Dose-dependent worsening of kidney function and acute kidney injury requiring dialysis have occurred.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation and injection-site reactions: Extravasation and injection-site reactions have occurred during administration. Ensure catheter and venous patency prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Scan interpretation: Use caution when interpreting a contrast-enhanced scan in the absence of a companion noncontrast MRI scan.</p></div>
<div class="block prod-avail drugH1Div" id="F57242045"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Vueway: FDA approved September 2022; anticipated availability currently unknown.</p></div>
<div class="block foc drugH1Div" id="F57397572"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elucirem: 0.5 mmol/mL (3 mL, 7.5 mL, 10 mL, 15 mL, 30 mL, 50 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vueway: 0.5 mmol/mL (3 mL, 7.5 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vueway: 0.5 mmol/mL (3 mL [DSC], 7.5 mL [DSC], 10 mL [DSC], 30 mL)</p></div>
<div class="block geq drugH1Div" id="F57397570"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57509865"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Elucirem Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mmol/mL (per mL): $13.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vueway Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mmol/mL (per mL): $13.46</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F57284508"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For IV use <b>only</b>. Solution should be clear and colorless to yellow without particulates; if solidification occurs with vials, bring vial and bulk package to room temperature before use. Prime IV line before use. Administer as a bolus injection at a rate of ~2 mL/second; if administering using a prefilled syringe, discard any unused portion following injection. Flush line with NS after administration to ensure complete injection of the contrast medium. Imaging can begin immediately following injection.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect; remove needle/cannula; elevate extremity. Aspiration of extravasated contrast media is not recommended. Information conflicts regarding the use of hyaluronidase; the American College of Radiology (ACR) Manual on Contrast Media does not recommend hyaluronidase in the management of contrast media extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>); other sources suggest its utility in extravasation management for inoperable cases with compartment syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>If using hyaluronidase</i>: <b>Intradermal or SUBQ:</b> Dose varies based on the size of infiltration; inject a total of 5 to 250 units (~100 mL contrast reabsorbed per 15 units of hyaluronidase) around the site of extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F57298816"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: For IV use only. Solution should be clear and colorless to yellow without particulates. Prime IV line before administration. Administer as a bolus injection at ~2 mL/second. Flush line with NS to ensure complete injection. Imaging can begin immediately after administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect; remove needle/cannula; elevate extremity. Aspiration of extravasated contrast media is not recommended (ACR 2022). Information is conflicting regarding the use of hyaluronidase; the American College of Radiology (ACR) Manual on Contrast Media does not recommend hyaluronidase in the management of contrast media extravasation (ACR 2022); other sources suggest its utility in extravasation management (see Management of Drug Extravasations for details) (Bellin 2002; Reynolds 2014).</p></div>
<div class="block meg drugH1Div" id="F57290272"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Elucirem: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F216986s000lbl.pdf%23page%3D17&amp;token=TnAE%2FxvN%2BrDUF5wcphrzssldSMmAG9Em7HD9f7UwyctSLwCnc3askuVUPkiqiGk8HlJxqsA9%2FmIeujLwaVkfKD02sZ%2Fo7Z23sUcAXsKgE4dqC93pmkFaSGMFOy7raW5U&amp;TOPIC_ID=139710" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216986s000lbl.pdf#page=17</a></p></div>
<div class="block use drugH1Div" id="F57242043"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Body imaging:</b> Contrast medium for MRI to visualize lesions with abnormal vascularity in head and neck, thorax, abdomen, pelvis, and musculoskeletal system in adults and pediatric patients ≥2 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS imaging:</b> Contrast medium for MRI to visualize lesions with abnormal vascularity in the brain, spine, and associated tissues in adults and pediatric patients ≥2 years of age.</p></div>
<div class="block cyt drugH1Div" id="F57277424"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F57277421"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F57284489"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to the use of gadolinium-based contrast agents in patients who may become pregnant (ACR 2022).</p></div>
<div class="block pri drugH1Div" id="F57284490"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;margin-left:0em;">Gadolinium-based contrast agents may cross the placenta (ACOG 2017; ACR 2022).</p>
<p style="text-indent:0em;margin-left:0em;margin-top:2em;">Pregnant patients may be at increased risk for gadolinium retention. Use of gadolinium-based contrast agents in pregnancy is controversial and should be limited. A gadolinium-based contrast agent with MRI may be considered for use in pregnancy if it will significantly improve diagnostic performance and is expected to improve fetal or maternal outcome (ACOG 2017). In addition, use should only be considered if information needed from the MRI study cannot be acquired without using a contrast agent and cannot be deferred until after delivery. Agents with a low risk for development of nephrogenic systemic fibrosis should be used at the lowest effective dose (ACR 2022).</p></div>
<div class="block brc drugH1Div" id="F57284491"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Gadolinium-based contrast agents may be present in breast milk (ACOG 2017; ACR 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">Because of the low expected excretion into breast milk and the low absorption from an infant's GI tract, breastfeeding may be continued without interruption after use (ACOG 2017; ACR 2022). Theoretically, the taste of milk could be altered if it contains contrast media. Patients who prefer to temporarily withhold breastfeeding may express and discard milk from both breasts during a period of 12 to 24 hours after the administration of contrast media. They can pump and store milk prior to the procedure then bottle feed using the stored milk during this time (ACR 2022). According to the manufacturer, the decision to breastfeed should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F57284515"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs of hypersensitivity (during and for several hours after procedure); kidney function (prior to administration); signs/symptoms of nephrogenic systemic fibrosis (eg, burning, itching, swelling, hardening and/or tightening of skin, joint stiffness, deep hip or rib bone pain, muscle weakness, limited range of motion, and/or yellowed/raised spots on whites of eye); monitor injection site for signs/symptoms of extravasation.</p></div>
<div class="block pha drugH1Div" id="F57284496"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Gadopiclenol is a paramagnetic molecule (macrocyclic non-ionic complex of gadolinium). When gadopiclenol is placed in a magnetic field, it develops a magnetic moment that relaxes water protons around it in the body leading to an increase in brightness of tissues.</p></div>
<div class="block phk drugH1Div" id="F57284497"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 13 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ≤1.8%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not metabolized.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 6 years: Median: 1.29 hours (range: 0.69 to 3.38 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 7 to 11 years: Median: 1.48 hours (range: 0.83 to 3.2 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents ≤17 years: Median: 1.77 hours (range: 1 to 3.57 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Mean: 1.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~98% within 48 hours).</p></div>
<div class="block phksp drugH1Div" id="F57284503"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Altered kidney function: Following a single 0.1 mmol/kg dose (2 times the recommended dose) to patients with estimated GFR of 15 to 90 mL/minute, clearance decreased and half-life increased in correlation with the degree of kidney impairment. Hemodialysis reduced blood concentrations by 95% to 98% after the first session and by 100% after the third session.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28937575">
<a name="28937575"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 723: Guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2017;130(4):e210-e216. doi:10.1097/AOG.0000000000002355<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopiclenol-drug-information/abstract-text/28937575/pubmed" id="28937575" target="_blank">28937575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.1">
<a name="ACR.1"></a>American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR manual on contrast media. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Published April 2023. Accessed May 17, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12386778">
<a name="12386778"></a>Bellin MF, Jakobsen JA, Tomassin I, et al; Contrast Media Safety Committee of the European Society of Urogenital Radiology. Contrast medium extravasation injury: guidelines for prevention and management. <i>Eur Radiol</i>. 2002;12(11):2807-2812. doi:10.1007/s00330-002-1630-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopiclenol-drug-information/abstract-text/12386778/pubmed" id="12386778" target="_blank">12386778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elucirem.1">
<a name="Elucirem.1"></a>Elucirem (gadopiclenol) injection [prescribing information]. Raleigh, NC: Liebel-Flarsheim Company LLC; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6628223">
<a name="6628223"></a>MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717. doi:10.1177/106002808301701002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopiclenol-drug-information/abstract-text/6628223/pubmed" id="6628223" target="_blank">6628223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi:10.1002/phar.1396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopiclenol-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22633726">
<a name="22633726"></a>Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.e1-e3. doi:10.1016/j.ajem.2012.03.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopiclenol-drug-information/abstract-text/22633726/pubmed" id="22633726" target="_blank">22633726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/gadopiclenol-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Vueway (gadopiclenol) injection [prescribing information]. Monroe Township, NJ: Bracco Diagnostics Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zenk.1">
<a name="Zenk.1"></a>Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>
</li></ol></div><div id="topicVersionRevision">Topic 139710 Version 35.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
